{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Sialorrhea",
    "query": {
      "condition": "Sialorrhea"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 12,
    "total_pages": 2,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Sialorrhea&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-05-22T08:21:42.816Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00491894",
      "title": "Safety and Efficacy Study of Oral Glycopyrrolate Liquid for the Treatment of Pathologic (Chronic Moderate to Severe) Drooling in Pediatric Patients 3 to 18 Years of Age With Cerebral Palsy or Other Neurologic Conditions",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Cerebral Palsy",
        "Neurological Conditions",
        "Mental Retardation",
        "Sialorrhea"
      ],
      "interventions": [
        {
          "name": "Oral Glycopyrrolate Liquid",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Shionogi",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "3 Years",
        "maximum_age": "18 Years",
        "sex": "ALL",
        "summary": "3 Years to 18 Years"
      },
      "enrollment_count": 137,
      "start_date": "2007-03",
      "completion_date": "2008-06",
      "has_results": true,
      "last_update_posted_date": "2012-07-09",
      "last_synced_at": "2026-05-22T08:21:42.816Z",
      "location_count": 7,
      "location_summary": "Lakewood, Colorado • Atlanta, Georgia • Bayside, New York + 4 more",
      "locations": [
        {
          "city": "Lakewood",
          "state": "Colorado"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Bayside",
          "state": "New York"
        },
        {
          "city": "Akron",
          "state": "Ohio"
        },
        {
          "city": "Mantua",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00491894"
    },
    {
      "nct_id": "NCT01565395",
      "title": "Incobotulinum Toxin A for Sialorrhea in Parkinson's Disease (PD)/Parkinsonism and Amyotrophic Lateral Sclerosis (ALS)",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Parkinson Disease",
        "Amyotrophic Lateral Sclerosis"
      ],
      "interventions": [
        {
          "name": "Incobotulinum Toxin A",
          "type": "DRUG"
        },
        {
          "name": "placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Beth Israel Deaconess Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "20 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "20 Years to 80 Years"
      },
      "enrollment_count": 0,
      "start_date": "2012-03",
      "completion_date": "2013-07",
      "has_results": false,
      "last_update_posted_date": "2017-02-07",
      "last_synced_at": "2026-05-22T08:21:42.816Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01565395"
    },
    {
      "nct_id": "NCT01370811",
      "title": "A Relative Efficacy and Safety Study of OC Oral Solution for Sialorrhoea in Patients With Parkinson's Disease",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Sialorrhoea"
      ],
      "interventions": [
        {
          "name": "oxybutynin and clonidine oral solution treatment A",
          "type": "DRUG"
        },
        {
          "name": "oxybutynin and clonidine oral solution treatment B",
          "type": "DRUG"
        },
        {
          "name": "oxybutynin and clonidine oral solution treatment C",
          "type": "DRUG"
        },
        {
          "name": "oxybutynin and clonidine oral solution treatment D",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Orient Pharma Co., Ltd.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "40 Years to 80 Years"
      },
      "enrollment_count": 24,
      "start_date": "2011-08",
      "completion_date": "2012-09",
      "has_results": true,
      "last_update_posted_date": "2023-04-10",
      "last_synced_at": "2026-05-22T08:21:42.816Z",
      "location_count": 1,
      "location_summary": "Bingham Farms, Michigan",
      "locations": [
        {
          "city": "Bingham Farms",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01370811"
    },
    {
      "nct_id": "NCT01191398",
      "title": "Effectiveness of Atropine and Glycopyrrolate to Reduce Hyper Salivation With Ketamine Sedation",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Sialorrhea"
      ],
      "interventions": [
        {
          "name": "Atropine (0.01mg/kg)",
          "type": "DRUG"
        },
        {
          "name": "Glycopyrrolate (0.01mg/kg)",
          "type": "DRUG"
        },
        {
          "name": "Normal saline 0.9%",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Craig J. Huang",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "6 Months",
        "maximum_age": "18 Years",
        "sex": "ALL",
        "summary": "6 Months to 18 Years"
      },
      "enrollment_count": 52,
      "start_date": "2010-06",
      "completion_date": "2011-01",
      "has_results": true,
      "last_update_posted_date": "2014-04-16",
      "last_synced_at": "2026-05-22T08:21:42.816Z",
      "location_count": 1,
      "location_summary": "Dallas, Texas",
      "locations": [
        {
          "city": "Dallas",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01191398"
    },
    {
      "nct_id": "NCT02234921",
      "title": "Pilot Study of DRibble Vaccine for Prostate Cancer Patients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Adenocarcinoma of the Prostate"
      ],
      "interventions": [
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "DRibble Vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "HPV Vaccinations",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Imiquimod",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL"
      ],
      "sponsor": "UbiVac",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "MALE",
        "summary": "Male only"
      },
      "enrollment_count": 3,
      "start_date": "2014-10-24",
      "completion_date": "2018-08-15",
      "has_results": false,
      "last_update_posted_date": "2018-10-11",
      "last_synced_at": "2026-05-22T08:21:42.816Z",
      "location_count": 1,
      "location_summary": "Portland, Oregon",
      "locations": [
        {
          "city": "Portland",
          "state": "Oregon"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02234921"
    },
    {
      "nct_id": "NCT00515437",
      "title": "A Multi-Center Study of MYOBLOC for the Treatment of Sialorrhea in Parkinson's Disease Patients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Drooling"
      ],
      "interventions": [
        {
          "name": "Botulinum Toxin Type B (Myobloc)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Matched placebo to Myobloc",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Solstice Neurosciences, LLC, a subsidiary of US WorldMeds, LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "18 Years to 85 Years"
      },
      "enrollment_count": 54,
      "start_date": "2007-07",
      "completion_date": "2008-09",
      "has_results": true,
      "last_update_posted_date": "2026-04-21",
      "last_synced_at": "2026-05-22T08:21:42.816Z",
      "location_count": 18,
      "location_summary": "Scottsdale, Arizona • Northridge, California • Oxnard, California + 15 more",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Northridge",
          "state": "California"
        },
        {
          "city": "Oxnard",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00515437"
    },
    {
      "nct_id": "NCT05164367",
      "title": "Pharmacokinetics of Atropine Oral Gel",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "EARLY_PHASE1"
      ],
      "conditions": [
        "Cerebral Palsy",
        "Sialorrhea"
      ],
      "interventions": [
        {
          "name": "Atropine sulfate gel (0.01%)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Utah",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "18 Years to 50 Years"
      },
      "enrollment_count": 10,
      "start_date": "2022-10-01",
      "completion_date": "2024-12-10",
      "has_results": false,
      "last_update_posted_date": "2024-12-18",
      "last_synced_at": "2026-05-22T08:21:42.816Z",
      "location_count": 1,
      "location_summary": "Salt Lake City, Utah",
      "locations": [
        {
          "city": "Salt Lake City",
          "state": "Utah"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05164367"
    },
    {
      "nct_id": "NCT01653132",
      "title": "Incobotulinum Toxin A (Xeomin®) for Troublesome Sialorrhea in Parkinson's Disease (PD)/Parkinsonism",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Sialorrhea"
      ],
      "interventions": [
        {
          "name": "Incobotulinum Toxin A",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Beth Israel Deaconess Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "90 Years",
        "sex": "ALL",
        "summary": "18 Years to 90 Years"
      },
      "enrollment_count": 10,
      "start_date": "2012-03",
      "completion_date": "2014-09",
      "has_results": true,
      "last_update_posted_date": "2017-03-14",
      "last_synced_at": "2026-05-22T08:21:42.816Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01653132"
    },
    {
      "nct_id": "NCT02610868",
      "title": "Open-Label and Single-Arm Study of MYOBLOC® in the Treatment of Troublesome Sialorrhea in Adults",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Sialorrhea"
      ],
      "interventions": [
        {
          "name": "MYOBLOC",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Solstice Neurosciences, LLC, a subsidiary of US WorldMeds, LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "18 Years to 85 Years"
      },
      "enrollment_count": 187,
      "start_date": "2015-10",
      "completion_date": "2017-06",
      "has_results": true,
      "last_update_posted_date": "2026-04-21",
      "last_synced_at": "2026-05-22T08:21:42.816Z",
      "location_count": 26,
      "location_summary": "Phoenix, Arizona • Scottsdale, Arizona • Loma Linda, California + 22 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Loma Linda",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02610868"
    },
    {
      "nct_id": "NCT00683891",
      "title": "FazaClo Outcomes in the Control of Schizophrenia (FOCUS) Study Survey",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Weight Gain",
        "Sialorrhea"
      ],
      "interventions": [
        {
          "name": "FazaClo (clozapine, USP) ODT",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Azur Pharma, Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": null,
      "start_date": null,
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2008-06-19",
      "last_synced_at": "2026-05-22T08:21:42.816Z",
      "location_count": 2,
      "location_summary": "Costa Mesa, California • Gastonia, North Carolina",
      "locations": [
        {
          "city": "Costa Mesa",
          "state": "California"
        },
        {
          "city": "Gastonia",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00683891"
    }
  ]
}